Thus, direct experiment in the lab (e.g., rt-qPCR) to compare the differential expression of PARP10 in AML and normal cells, and association analysis of PARP10 expression with clinical prognosis in the current treatment cohort are warranted to perform in the future. Here, PARP10 is linked to acute myeloid leukemia.